C-terminal Mutants of Apolipoprotein L-I Efficiently Kill Both Trypanosoma Brucei Brucei and Trypanosoma Brucei Rhodesiense

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2009 Dec 10

PMID 19997494

Citations 59

Authors

Laurence Lecordier

Benoit Vanhollebeke

Philippe Poelvoorde

Patricia Tebabi

Francoise Paturiaux-Hanocq

Fabienne Andris

Laurence Lins

Etienne Pays

Affiliations

Soon will be listed here.

Abstract

Apolipoprotein L-I (apoL1) is a human-specific serum protein that kills Trypanosoma brucei through ionic pore formation in endosomal membranes of the parasite. The T. brucei subspecies rhodesiense and gambiense resist this lytic activity and can infect humans, causing sleeping sickness. In the case of T. b. rhodesiense, resistance to lysis involves interaction of the Serum Resistance-Associated (SRA) protein with the C-terminal helix of apoL1. We undertook a mutational and deletional analysis of the C-terminal helix of apoL1 to investigate the linkage between interaction with SRA and lytic potential for different T. brucei subspecies. We confirm that the C-terminal helix is the SRA-interacting domain. Although in E. coli this domain was dispensable for ionic pore-forming activity, its interaction with SRA resulted in inhibition of this activity. Different mutations affecting the C-terminal helix reduced the interaction of apoL1 with SRA. However, mutants in the L370-L392 leucine zipper also lost in vitro trypanolytic activity. Truncating and/or mutating the C-terminal sequence of human apoL1 like that of apoL1-like sequences of Papio anubis resulted in both loss of interaction with SRA and acquired ability to efficiently kill human serum-resistant T. b. rhodesiense parasites, in vitro as well as in transgenic mice. These findings demonstrate that SRA interaction with the C-terminal helix of apoL1 inhibits its pore-forming activity and determines resistance of T. b. rhodesiense to human serum. In addition, they provide a possible explanation for the ability of Papio serum to kill T. b. rhodesiense, and offer a perspective to generate transgenic cattle resistant to both T. b. brucei and T. b. rhodesiense.

Citing Articles

Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease.

Pays E Cells. 2024; 13(20.

PMID: 39451256 PMC: 11506758. DOI: 10.3390/cells13201738.

IFI16 Is Indispensable for Promoting HIF-1α-Mediated APOL1 Expression in Human Podocytes under Hypoxic Conditions.

Randle R, Amara V, Popik W Int J Mol Sci. 2024; 25(6).

PMID: 38542298 PMC: 10970439. DOI: 10.3390/ijms25063324.

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.

Iyer R, Needham S, Galdadas I, Davis B, Roberts S, Man R Nat Commun. 2024; 15(1):2130.

PMID: 38503739 PMC: 10951324. DOI: 10.1038/s41467-024-46284-x.

The Janus-faced functions of Apolipoproteins L in membrane dynamics.

Pays E Cell Mol Life Sci. 2024; 81(1):134.

PMID: 38478101 PMC: 10937811. DOI: 10.1007/s00018-024-05180-9.

The role of invariant surface glycoprotein 75 in xenobiotic acquisition by African trypanosomes.

Makarov A, Began J, Mautone I, Pinto E, Ferguson L, Zoltner M Microb Cell. 2023; 10(2):18-35.

PMID: 36789350 PMC: 9896412. DOI: 10.15698/mic2023.02.790.

References

Kobayashi N, Nishikawa M, Hirata K, Takakura Y . Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med. 2004; 6(5):584-92. DOI: 10.1002/jgm.541. View

Thomas A, Deshayes S, Decaffmeyer M, Van Eyck M, Charloteaux B, Brasseur R . Prediction of peptide structure: how far are we?. Proteins. 2006; 65(4):889-97. DOI: 10.1002/prot.21151. View

Wirtz E, Leal S, Ochatt C, Cross G . A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol. 1999; 99(1):89-101. DOI: 10.1016/s0166-6851(99)00002-x. View

Poelvoorde P, Vanhamme L, Van Den Abbeele J, Switzer W, Pays E . Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. Mol Biochem Parasitol. 2004; 134(1):155-7. DOI: 10.1016/j.molbiopara.2003.11.006. View

Duchateau P, Pullinger C, Cho M, Eng C, Kane J . Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res. 2001; 42(4):620-30. View

Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan D, Perez-Morga D . The trypanolytic factor of human serum. Nat Rev Microbiol. 2006; 4(6):477-86. DOI: 10.1038/nrmicro1428. View

Gaboriaud C, Bissery V, Benchetrit T, Mornon J . Hydrophobic cluster analysis: an efficient new way to compare and analyse amino acid sequences. FEBS Lett. 1987; 224(1):149-55. DOI: 10.1016/0014-5793(87)80439-8. View

Callebaut I, Labesse G, Durand P, Poupon A, Canard L, Chomilier J . Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives. Cell Mol Life Sci. 1997; 53(8):621-45. PMC: 11147222. DOI: 10.1007/s000180050082. View

Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan D, Lins L, Homble F . Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science. 2005; 309(5733):469-72. DOI: 10.1126/science.1114566. View

10.

Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan D, Lins L, Van Den Abbeele J . Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003; 422(6927):83-7. DOI: 10.1038/nature01461. View

11.

Molina-Portela M, Samanovic M, Raper J . Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med. 2008; 205(8):1721-8. PMC: 2525602. DOI: 10.1084/jem.20071463. View

12.

Lugli E, Pouliot M, Portela M, Loomis M, Raper J . Characterization of primate trypanosome lytic factors. Mol Biochem Parasitol. 2004; 138(1):9-20. DOI: 10.1016/j.molbiopara.2004.07.004. View

13.

Hirumi H, Hirumi K . Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol. 1989; 75(6):985-9. View

14.

Baltz T, Baltz D, Giroud C, Crockett J . Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 1985; 4(5):1273-7. PMC: 554336. DOI: 10.1002/j.1460-2075.1985.tb03772.x. View

15.

Vanhollebeke B, De Muylder G, Nielsen M, Pays A, Tebabi P, Dieu M . A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science. 2008; 320(5876):677-81. DOI: 10.1126/science.1156296. View

16.

KAGERUKA P, Mangus E, Bajyana Songa E, Nantulya V, Jochems M, HAMERS R . Infectivity of Trypanosoma (Trypanozoon) brucei gambiense for baboons (Papio hamadryas, Papio papio). Ann Soc Belg Med Trop. 1991; 71(1):39-46. View

17.

Vanhollebeke B, Lecordier L, Perez-Morga D, Amiguet-Vercher A, Pays E . Human serum lyses Trypanosoma brucei by triggering uncontrolled swelling of the parasite lysosome. J Eukaryot Microbiol. 2007; 54(5):448-51. DOI: 10.1111/j.1550-7408.2007.00285.x. View

18.

Xong H, Vanhamme L, Chamekh M, Chimfwembe C, Van Den Abbeele J, Pays A . A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell. 1998; 95(6):839-46. DOI: 10.1016/s0092-8674(00)81706-7. View

19.

de Greef C, Chimfwembe E, Kihanga Wabacha J, Bajyana Songa E, HAMERS R . Only the serum-resistant bloodstream forms of Trypanosoma brucei rhodesiense express the serum resistance associated (SRA) protein. Ann Soc Belg Med Trop. 1992; 72 Suppl 1:13-21. View

20.

Melo F, Feytmans E . Assessing protein structures with a non-local atomic interaction energy. J Mol Biol. 1998; 277(5):1141-52. DOI: 10.1006/jmbi.1998.1665. View